Based on this mechanism, it is easy to conceive that as the Keap1-Nrf2 or PI3K-AKT signalling pathway is activated by increased ROS, cancer cells are facilitated with the ability to resist the prooxidant therapy-meditated generation of ROS, resulting in radio- and chemoresistance. This evidence concerns the gene NFE2L2 and cancer.